THE IMPACT OF OAB CAN BE FELT EVERYWHERE, BUT THERE IS A TREATMENT THAT MAY HELP
No overall differences in safety or effectiveness of GEMTESA® have been observed between patients aged 65+ and younger adult patients.1
CHOOSE GEMTESA TO MANAGE OVERACTIVE BLADDER (OAB): Proven efficacy data in all 3 key OAB symptoms* in its label vs. placebo at 12 weeks2,3†
One crushable dose, no titration - To be taken with or without food and swallowed with a glass of water2 - May be crushed, mixed with a tablespoon (~15 mL) of applesauce and taken immediately with a glass of water2
No blood pressure warning in its label2 No drug interaction with CYP2D6 substrates (medications commonly taken by long-term care residents)2,4
- Digoxin drug interaction was identified with GEMTESA. Measure serum digoxin concentrations before initiating GEMTESA. Monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. Continue monitoring digoxin concentrations upon discontinuation of GEMTESA and adjust digoxin dose as needed2
= The first & only β3 -agonist with...
As many residents may suffer from cognitive decline, they may have difficulty reporting OAB symptoms. Here’s what to look for3,5,6
:
Urgency (the hallmark symptom): Sudden, strong urge to urinate immediately
Urge urinary incontinence/leakage: Involuntary leakage episodes (which may require use of absorbent products)
*The 3 key symptoms of OAB are urgency, micturition frequency, and urge urinary incontinence (UUI)/leakage.3 †
Frequency: Urinating 8+ times per day
The efficacy of GEMTESA was evaluated in a pivotal 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.2,7
INDICATION AND USAGE GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
